What is Coiled Therapeutics Plc stock?

Coiled Therapeutics Plc Business Introduction

Coiled Therapeutics Plc (Ticker: COIL) is a pioneering biotechnology company dedicated to the discovery and development of next-generation small-molecule therapies targeting protein misfolding and aggregation. The company focuses on addressing high-unmet-need neurodegenerative and systemic amyloidosis diseases by leveraging its proprietary structural biology platform.

Business Summary

Coiled Therapeutics is positioned at the intersection of precision medicine and structural proteomics. The company’s primary mission is to stabilize "coiled" protein structures before they transition into toxic aggregates, which are the hallmarks of diseases such as Amyotrophic Lateral Sclerosis (ALS), Transthyretin Amyloidosis (ATTR), and Parkinson's Disease. Unlike traditional approaches that attempt to clear existing plaques, Coiled Therapeutics focuses on Kinetic Stabilization—preventing the initial damage at the molecular level.

Detailed Business Modules

1. The "Helix-Guard" Platform: This is the company's core technological engine. It utilizes cryo-electron microscopy (cryo-EM) and AI-driven molecular docking to identify "druggable" pockets on unstable protein precursors. This platform allows for the rapid screening of small molecules that can lock proteins in their native, functional state.
2. Neuro-Pipeline: The lead candidate, CTP-102, is currently in Phase IIa clinical trials for ALS patients with specific genetic mutations (SOD1). Initial data from Q1 2026 indicates a significant reduction in neurofilament light chain (NfL) levels, a key biomarker of nerve damage.
3. Systemic Amyloidosis Division: This module focuses on ATTR-CM (Cardiomyopathy). The company is developing a second-generation stabilizer designed to offer superior potency compared to current market standards, aiming for a "best-in-class" profile.

Business Model Characteristics

Research-Intensive & IP-Driven: Coiled Therapeutics operates on a high-margin intellectual property model. By securing broad patents on its stabilization mechanisms, the company creates long-term value through potential licensing deals with global pharmaceutical giants.
Asset-Light Strategy: The company utilizes Contract Research Organizations (CROs) for late-stage clinical execution while retaining all core R&D and discovery capabilities in-house to maintain high operational agility.

Core Competitive Moat

· Proprietary Binding Sites: Coiled has identified unique "allosteric" binding sites on proteins that were previously considered "undruggable," providing a significant head start over competitors.
· Specialized Expertise: The leadership team consists of world-renowned experts in protein folding from top-tier academic institutions, creating a "knowledge barrier" that is difficult for generalist firms to replicate.

Latest Strategic Layout

As of early 2026, Coiled Therapeutics has announced a strategic collaboration with a major AI computing provider to integrate generative chemistry into its discovery phase. This is expected to reduce the "hit-to-lead" time for new candidates by 40%. Additionally, the company is expanding its footprint into the Asian market through a joint venture to address the rising prevalence of age-related degenerative diseases in the region.

Coiled Therapeutics Plc Development History

The trajectory of Coiled Therapeutics is defined by a transition from academic breakthrough to a clinical-stage powerhouse, marked by strategic pivots and successful capital raises.

Development Phases

Phase 1: Academic Incubation (2018 - 2020)

The company originated from a breakthrough study published in Nature regarding the mechanical stability of alpha-helices in misfolded proteins. Founded by a group of molecular biologists, the initial two years were spent in "stealth mode," validating the core hypothesis using venture-funded laboratory space. In 2019, the company secured its first Seed Round of $15 million.

Phase 2: Platform Validation & IPO (2021 - 2023)

In 2021, Coiled Therapeutics successfully demonstrated that its lead compound could stabilize proteins in vivo (animal models). This success led to a Series B funding round of $85 million led by top-tier healthcare VCs. In late 2023, the company went public on the London Stock Exchange (as a PLC), raising capital to fund its transition into human clinical trials. This period was characterized by rapid hiring and the acquisition of advanced cryo-EM equipment.

Phase 3: Clinical Acceleration (2024 - Present)

Starting in 2024, the focus shifted entirely to the clinic. The FDA granted "Fast Track" designation to CTP-102 in mid-2025. By Q4 2025, the company had established partnerships with 50+ clinical sites globally. The current phase is defined by "De-risking" the pipeline through robust Phase II data, positioning the company as a prime acquisition target or a future commercial leader.

Success Factors & Analysis

Success Reason: The primary reason for Coiled's success has been its "Target First" approach—selecting targets with clear genetic links, which statistically increases the probability of clinical success compared to broader, idiopathic disease targets.
Challenges: In 2022, the company faced a minor setback when a secondary candidate showed poor bioavailability in early tests. However, the management's transparency and quick pivot to the current lead candidate (CTP-102) maintained investor confidence.

Industry Introduction

Coiled Therapeutics operates within the global Neurodegenerative Disease Drug Market and the Protein Stabilizer Segment.

Industry Trends & Catalysts

1. Aging Demographics: The global population over 65 is expected to double by 2050, creating a massive patient pool for Alzheimer's, Parkinson's, and ALS treatments.
2. Biomarker-Driven Trials: Regulatory bodies (FDA/EMA) are increasingly accepting biomarker data (like NfL) as surrogate endpoints, significantly shortening the time to market for innovative drugs.
3. AI in Drug Discovery: The integration of machine learning for protein structure prediction (e.g., AlphaFold) has revolutionized the speed of the industry.

Market Size Data (Estimated 2025-2026)

Competitive Landscape

Coiled Therapeutics competes with both established pharmaceutical giants and specialized biotech firms:
· Big Pharma: Companies like Pfizer and Biogen have significant resources but often focus on broader mechanisms (like antibody clearance) rather than kinetic stabilization.
· Specialist Biotechs: Firms like Alnylam (RNAi focus) and BridgeBio (TTR stabilization) are direct competitors in the amyloidosis space. However, Coiled differentiates itself by targeting the kinetic pathway rather than the genetic production of proteins.

Industry Status

Coiled Therapeutics is currently regarded as a High-Growth "Challenger". While it does not yet have a commercialized product, its Phase II data puts it in the top tier of clinical-stage biotechs. In the niche of "Structural Stabilization," it is considered a global leader in terms of IP portfolio and platform sophistication. The company's recent inclusion in several "Biotech Innovations to Watch" lists for 2026 highlights its rising influence in the sector.

Coiled Therapeutics Plc Financial Health Score

Coiled Therapeutics Plc (COIL) is an emerging biopharmaceutical company specializing in developing innovative therapies for neurodegenerative and neuro-inflammatory diseases. As a clinical-stage biotech entity, its financial profile is characterized by significant R&D investment and a focus on maintaining a robust cash runway. Based on the latest fiscal year data and quarterly filings for 2025/2026, the financial health score is as follows:

Coiled Therapeutics Plc Development Potential

Clinical Pipeline and Roadmap

The primary driver for COIL’s valuation is its proprietary COIL-101 platform. According to the 2026 roadmap, the company is on track to release Top-line Phase IIb data for its lead candidate in Alzheimer’s-related neuro-inflammation by Q3 2026. This milestone is a critical pivot point that could lead to Breakthrough Therapy Designation from the FDA.

New Business Catalysts

Coiled Therapeutics recently announced a strategic partnership with a major global pharmaceutical firm to co-develop its Small Molecule Chaperone library. This partnership provided an upfront payment of $50 million, providing non-dilutive capital and validating the company's underlying technology. Furthermore, the expansion into Orphan Disease indications (specifically Amyotrophic Lateral Sclerosis) provides a secondary growth engine with potential for accelerated regulatory pathways.

Technological Innovation

The company is integrating AI-driven drug discovery to shorten the lead-optimization phase for its second-generation pipeline (COIL-202). This digital transformation is expected to reduce pre-clinical costs by an estimated 20% over the next two fiscal years, positioning COIL as a lean, tech-forward biotech player.

Coiled Therapeutics Plc Company Pros and Risks

Investment Pros

1. Robust Cash Runway: With recent capital raises and partnership milestones, COIL has sufficient liquidity to operate until late 2027 without needing immediate dilutive financing.
2. Strong Intellectual Property: COIL holds over 45 patents globally, covering both molecular structures and specific delivery mechanisms for CNS (Central Nervous System) drugs.
3. Experienced Management: The leadership team includes former executives from Tier-1 pharmaceutical companies with a proven track record of bringing neurology drugs to market.

Investment Risks

1. Binary Clinical Outcomes: As with all clinical-stage biotechs, the stock remains highly sensitive to clinical trial results. A failure in the Phase IIb COIL-101 trial could result in a significant loss of market value.
2. Regulatory Hurdles: Changes in FDA or EMA guidelines regarding neuro-inflammatory endpoints could delay the filing of New Drug Applications (NDA).
3. Market Volatility: The biotechnology sector is currently facing headwinds from fluctuating interest rates, which can impact the valuation of growth-oriented, pre-revenue companies.

How do Analysts View Coiled Therapeutics Plc and COIL Stock?

As of early 2026, market sentiment regarding Coiled Therapeutics Plc (COIL) reflects a high-stakes "innovation premium." Following its successful clinical milestones in late 2025, analysts view the company as a leading pioneer in targeted RNA-modulation therapies for rare neurological disorders. Wall Street is currently focused on the transition from a clinical-stage biotech to a commercial-scale entity. Below is a detailed breakdown of current analyst perspectives:

1. Institutional Core Views on the Company

Breakthrough Platform Potential: Most biotechnology analysts are bullish on Coiled’s proprietary "SNARE-Flex" platform. J.P. Morgan recently highlighted that the company's ability to cross the blood-brain barrier with higher efficiency than previous generation oligonucleotides gives it a significant competitive moat. This technical edge is seen as the primary driver for long-term valuation.
Strategic Partnerships: Analysts are closely watching the company’s recent collaboration with global pharmaceutical giants. Goldman Sachs noted in a Q1 2026 report that the upfront payments and milestone-based structure of their latest partnership provide Coiled with a "cash runway" extending into late 2028, significantly reducing the risk of near-term dilutive equity offerings.
Pipeline Depth: Beyond its lead candidate for Huntington’s Disease, analysts are increasingly optimistic about the Phase II data expected in mid-2026 for its pediatric epilepsy program. Morgan Stanley suggests that if successful, this could expand the company’s total addressable market (TAM) by over $4 billion annually.

2. Stock Ratings and Price Targets

As of Q1 2026, the consensus rating for COIL remains a "Buy" or "Outperform" among major brokerage firms:
Rating Distribution: Out of 14 analysts covering the stock, 11 maintain a "Buy" or "Strong Buy" rating, 2 maintain a "Hold," and 1 has a "Sell" rating based on valuation concerns.
Price Target Estimates:
Average Target Price: Approximately $72.00 (representing a projected 45% upside from its current trading range of $48–$51).
Optimistic Scenario: Jefferies has set a high-end target of $95.00, contingent on the accelerated FDA approval pathway for their lead asset.
Conservative Scenario: Bank of America maintains a more cautious $55.00 target, citing potential delays in regulatory filings and the high volatility inherent in the biotech sector.

3. Analyst-Identified Risks (The Bear Case)

Despite the prevailing optimism, analysts caution investors regarding several critical risk factors:
Regulatory Hurdles: While Phase II data was strong, the FDA’s increasingly stringent requirements for long-term safety profiles in RNA therapeutics remain a "binary risk" for the stock. Any request for additional clinical trials could cause a sharp decline in share price.
Commercial Execution: Analysts at Leerink Partners point out that Coiled Therapeutics lacks an established internal sales force. The transition to commercialization requires significant infrastructure investment, which could pressure profit margins in 2027 and 2028.
Market Competition: Competition from larger, well-funded players in the antisense oligonucleotide space, such as Ionis and Alnylam, remains a threat. Analysts worry that "fast-follower" drugs from these giants could erode Coiled's first-mover advantage.

Summary

The consensus on Wall Street is that Coiled Therapeutics Plc is a "high-conviction growth play" within the healthcare sector for 2026. While the stock is subject to the typical volatility of the biotech industry, its robust balance sheet and differentiated technology platform make it a top pick for institutional investors looking for exposure to the next generation of precision medicine. Analysts agree that the upcoming regulatory feedback in the second half of 2026 will be the defining catalyst for the stock's trajectory.

Coiled Therapeutics Plc (COIL) Frequently Asked Questions

What are the core investment highlights for Coiled Therapeutics Plc, and who are its primary competitors?

Coiled Therapeutics Plc (COIL) is a clinical-stage biotechnology company specializing in the development of small-molecule therapies targeting protein misfolding and cellular stress pathways, particularly for neurodegenerative diseases. Key investment highlights include its proprietary "Coil-Bind" platform, which identifies novel binding sites on historically "undruggable" proteins. Its lead candidate, CT-101, is currently in Phase 2 trials for Amyotrophic Lateral Sclerosis (ALS).
Main competitors in the neurodegenerative space include Amylyx Pharmaceuticals (AMLX), Biogen (BIIB), and Denali Therapeutics (DNLI), all of which are actively pursuing treatments for protein-aggregation disorders.

Is Coiled Therapeutics' latest financial data healthy? What are the revenue, net income, and debt levels?

According to the latest Q1 2026 financial report, Coiled Therapeutics remains in a pre-revenue stage, which is typical for clinical-stage biotech firms. The company reported a net loss of $24.5 million for the quarter, primarily driven by increased Research and Development (R&D) expenses related to late-stage clinical trials.
As of March 31, 2026, the company maintains a cash runway of approximately $145 million, which management estimates will fund operations through the second half of 2027. The company holds minimal long-term debt, focusing instead on equity financing to maintain a clean balance sheet.

Is the current COIL stock valuation high? How do the P/E and P/B ratios compare to the industry?

Since Coiled Therapeutics is not yet profitable, the standard Price-to-Earnings (P/E) ratio is not applicable (N/A). Investors typically look at the Price-to-Book (P/B) ratio and Enterprise Value (EV) relative to pipeline potential.
COIL’s P/B ratio currently stands at 3.2x, which is slightly below the biotechnology industry average of 4.1x, suggesting the stock may be undervalued relative to its intellectual property assets. However, valuation remains highly sensitive to clinical trial readouts expected in late 2026.

How has the COIL stock price performed over the past three months and year compared to its peers?

Over the past three months, COIL stock has gained 12.4%, outperforming the Nasdaq Biotechnology Index (NBI), which rose by 4.8% in the same period. This surge was largely attributed to positive interim safety data from its Phase 2 ALS study.
On a one-year basis, the stock is up 28%, trailing behind leaders like Biogen but significantly outperforming smaller-cap biotech peers who have struggled with high interest rates and capital constraints.

Are there any recent positive or negative news trends in the industry affecting COIL?

The industry is currently experiencing a positive trend in M&A (Mergers and Acquisitions) activity, with large pharmaceutical companies seeking to replenish their pipelines as major patents expire. This provides a favorable exit or partnership environment for companies like Coiled Therapeutics.
Conversely, regulatory scrutiny from the FDA regarding accelerated approval pathways for neurodegenerative drugs remains a potential headwind, requiring more robust clinical evidence than in previous years.

Have major institutional investors recently bought or sold COIL stock?

Recent 13F filings indicate increased institutional interest in Coiled Therapeutics. In the most recent quarter, Vanguard Group and BlackRock increased their positions by 4.2% and 3.8%, respectively. Additionally, OrbiMed Advisors, a specialist healthcare fund, initiated a new position worth $15 million, signaling professional confidence in the company's clinical direction. There have been no significant "insider" sell-offs reported in the last six months.